Number of Attending Physicians and Accumulated Organ Damage in Patients with Systemic Lupus Erythematosus: LUNA Registry Cross-Sectional Study

Yanai, Ryo; Yajima, Nobuyuki; Oguro, Nao; Shimojima, Yasuhiro; Ohno, Shigeru; Kajiyama, Hiroshi; Ichinose, Kunihiro; Sato, Shuzo; Fujiwara, Michio; Miyawaki, Yoshia; Yoshimi, Ryusuke; Kida, Takashi; Matsuo, Yusuke; Nishimura, Keisuke; Sada, Ken-Ei

doi:10.1007/s40744-022-00528-8

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a UK cohort study (n=936), the accrual of damage within 5 years in newly-diagnosed SLE patients was significantly associated with increased annualised per-patient costs, with higher primary (care and prescriptions) and secondary (hospital admission and emergency) healthcare resource use (34). Opposingly, it should be noted that damage accrual, particularly glucocorticoid-related (OR 1.22, 95%CI 1.09-1.38), was associated with the number of attending physicians in a multicentre cohort study from Japan (35), thus claiming for a careful thinking of the structure of the Lupus Clinics in developing phases. However, it must be underlined that the concept of "SLErelated damage" is not static in its nature.…”

Section: Comorbidities and Organ Damagementioning

confidence: 99%

Systemic lupus erythematosus: one year in review 2024

Schilirò,

Silvagni,

Ciribè

et al. 2024

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is classically regarded as the landmark of systemic autoimmune diseases, characterised by protean, multi-systemic manifestations and a highly variable clinical course. Over the last years, both clinical and translational clinical research efforts led to significant steps forward in management and treatment of SLE. However, numerous aspects of SLE, from pathogenesis to treatment, still remain challenging, and several unmet needs persist for both patients and physicians. Following the previous annual reviews of this series, herewith, we aim to report the most relevant new updates on SLE, issued in 2023. In particular, we focused on biomarkers, clinical aspects and outcomes, comorbidities, as well as new treatment targets and realworld evidence.

show abstract

Section: Comorbidities and Organ Damagementioning

confidence: 99%

Systemic lupus erythematosus: one year in review 2024

Schilirò,

Silvagni,

Ciribè

et al. 2024

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

show abstract

Damage in rheumatic diseases: Contemporary international standpoint and scores emerging from clinical, radiological and machine learning

Tharwat,

El-Gazzar,

El Shereef

et al. 2024

The Egyptian Rheumatologist

View full text Add to dashboard Cite

Clinical and economic burden of organ damage among patients with systemic lupus erythematosus in a real-world setting in Germany

Schultze,

Garal-Pantaler,

Pignot

et al. 2024

BMC Rheumatol

View full text Add to dashboard Cite

Background Systemic lupus erythematosus (SLE), a chronic multisystem autoimmune disease, carries high risk of organ damage and burden to healthcare systems. SLE disease modification aims to reduce disease activity with minimal treatment toxicity and preventing or minimizing organ damage development. This real-world study utilizing healthcare administrative claims data assessed organ damage development, associated costs and healthcare resource utilization (HCRU) in patients with SLE in Germany. Methods Claims data from January 1, 2007, to December 31, 2017, were obtained from the Betriebskrankenkassen German Sickness Fund Database. Adults (> 18 years) with a confirmed SLE diagnosis between January 1, 2009, and December 31, 2014, (inclusion period) were included. The index date was calculated based on the first recorded SLE diagnosis during this period. Patients were propensity score–matched (1:3) to a comparator cohort without SLE by age, sex, and comorbidities (Charlson comorbidity index). Organ damage was identified using an algorithm developed based on conditions described in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI), using ICD-10-GM diagnostic codes, healthcare procedures, and/or treatments. Results 2121 patients with SLE and 6308 comparator patients were included (mean follow-up time: 6.4 years). Organ damage prevalence increased from 60.5% at baseline to 83.0% during 6 years of follow-up in all patients with SLE, while 17.0% of patients with SLE did not develop organ damage. Patients with newly confirmed SLE diagnosis without organ damage at baseline were nearly twice as likely to develop organ damage within 5 years versus the comparator cohort (52.0% vs. 27.0%). Total annual costs per patient-year for patients with SLE with organ damage were more than double those of patients with SLE without organ damage; both the number of inpatient admissions and length of stay were higher. Conclusions The application of a recently developed algorithm allowed us to use claims data to elucidate SLE organ damage, and its associated high clinical and economic burden, in a large, representative sample in Germany. To our knowledge, this is the first European analysis of its kind involving a broad cohort of patients with SLE treated in the routine care setting.

show abstract

Number of Attending Physicians and Accumulated Organ Damage in Patients with Systemic Lupus Erythematosus: LUNA Registry Cross-Sectional Study

Cited by 3 publications

References 21 publications

Systemic lupus erythematosus: one year in review 2024

Systemic lupus erythematosus: one year in review 2024

Damage in rheumatic diseases: Contemporary international standpoint and scores emerging from clinical, radiological and machine learning

Clinical and economic burden of organ damage among patients with systemic lupus erythematosus in a real-world setting in Germany

Contact Info

Product

Resources

About